CASE REPORT article
Front. Endocrinol.
Sec. Clinical Diabetes
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1501984
This article is part of the Research TopicMetabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) - Pathogenesis, Prevention and TreatmentView all 11 articles
Case report: Amelioration of severe metabolic dysfunction-associated steatohepatitis switching from conventional GLP-1RAs to tirzepatide
Provisionally accepted- 1Kushiro Red-Cross Hospital, Kushiro, Japan
- 2Hokkaido University, Sapporo, Hokkaidō, Japan
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Metabolic dysfunction-associated steatohepatitis (MASH) contains cardiometabolic risk factors, such as obesity and type 2 diabetes, and has been reported potential higher risks of mortality than conventional steatotic liver diseases. Liver fibrosis develops and can progress to cirrhosis and hepatocellular carcinoma. Although some antidiabetic agents have been reported to ameliorate the condition, no specific medical treatment has been developed to date. Tirzepatide is a dual glucosedependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that has shown efficacy against MASH in some clinical trials. However, these subjects were limited to those with mild-to-moderate fibrosis and their history of treatment was often unclear. Here, we report the case of a 50-year-old man with a 16-year history of diabetes. He demonstrated poor control of his diabetes with elevated liver enzyme. Liver biopsy was performed and he was diagnosed with "Steatohepatitis". Liraglutide was administered for 3 years, but his liver function and glycemic control deteriorated gradually and a second liver biopsy was performed in 2023. The histologic finding was "Cirrhosis" and liraglutide was switched to tirzepatide. Over 6 months of administration of tirzepatide, the patient's glycated hemoglobin and elevated liver enzyme improved. A third biopsy was performed, which showed a marked improvement in histology, with the amelioration of liver fibrosis. A diagnosis of "Steatotic liver disease" was made. Although some previous studies had demonstrated an amelioration of liver fibrosis and an improvement in the prognosis of patients following GLP-1 receptor agonists (GLP-1RAs) treatment, effective medications for patients with severe fibrosis or who are refractory to treatment with GLP-1RAs has not been identified to date. We reported a case with severe MASH who had ameliorated by switching from conventional GLP-1RAs to tirzepatide.
Keywords: Glucose-dependent insulinotropic polypeptide, Glucagon-like peptide 1 receptor, type 2 diabetes, metabolic dysfunction-associated steatohepatitis, Obesity
Received: 26 Sep 2024; Accepted: 25 Apr 2025.
Copyright: © 2025 Oe, Omori, Aimono, Furukawa, Kitakawa, Tateno and Sakai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yuki Oe, Kushiro Red-Cross Hospital, Kushiro, Japan
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.